|
| 不同类型他汀在皮层脑梗死后癫痫中的价值比较* |
| Comparison of the value of different types of statins in epilepsy after cortical cerebral infarction |
| 投稿时间：2024-02-26 修订日期：2024-03-13 |
| DOI： |
| 中文关键词: 卒中后癫痫 皮层脑梗死 他汀 |
| 英文关键词: post-stroke epilepsy Cortical cerebral infarction Statin |
| 基金项目:江西省卫健委科技计划,编号202130060 |
|
| 摘要点击次数: 75 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探讨不同类型他汀降低皮层脑梗死后癫痫的价值。方法 选取2016年1月至2023年2月在我院神经内科就诊,首次发生急性皮层脑梗死,既往无癫痫病史者,共纳入800例。将未接受他汀治疗者纳入空白组,共纳入200例。其余患者随机接受阿托伐他汀,瑞舒伐他汀,辛伐他汀治疗,分别纳入阿托伐他汀、瑞舒伐他汀、辛伐他汀治疗组,每组各纳入200例。比较各组卒中后癫痫发生率、发作类型,监测他汀治疗组肝肾功能、肌酶水平。结果 空白组脑梗死后癫痫发生率明显高于阿托伐他汀、瑞舒伐他汀及辛伐他汀治疗组,阿托伐他汀组发生率最低,差异具有统计学意义(P＜0.05)。空白组各种类型癫痫发作最多,其次为辛伐他汀组,而阿托伐他汀组发作最少,差异具有统计学意义(P＜0.05)。阿托伐他汀组、瑞舒伐他汀组、辛伐他汀组均发生肝肾功能、肌酶明显升高的不良反应,但两两比较,差异无统计学意义(P＞0.05)。结论 他汀可降低皮层脑梗死后癫痫的发生,阿托伐他汀在降低癫痫发生率、减少癫痫发作类型方面优于瑞舒伐他汀和辛伐他汀,且不增加肝肾功能损害及肌酶升高的副作用,是治疗皮层脑梗死后癫痫安全、有效的药物。 |
| 英文摘要: |
| Objective To explore the value of different types of statins in reducing epilepsy after cortical cerebral infarction. Methods From January 2016 to February 2023, 800 patients with acute cerebral infarction and no history of epilepsy were enrolled. 200 patients without statin treatment were included in the blank group. The other patients were randomly treated with atorvastatin, rosuvastatin and simvastatin, and were included in the atorvastatin, rosuvastatin and simvastatin treatment groups, with 200 patients in each group. Compare the incidence and type of epilepsy after stroke in each group, and monitor the liver and kidney function and muscle enzyme level in the statin treatment group. Results The incidence of epilepsy after cerebral infarction in the blank group was significantly higher than that in the atorvastatin, rosuvastatin and simvastatin treatment groups. The incidence of epilepsy in the atorvastatin group was the lowest, and the difference was statistically significant (P<0.05). The blank group had the most seizures of all types, followed by the simvastatin group, and the atorvastatin group had the least seizures, with a statistically significant difference (P<0.05). The atorvastatin group, rosuvastatin group and simvastatin group all had adverse reactions with significantly increased liver and kidney function and muscle enzyme, but there was no significant difference between the two groups (P>0.05). Conclusion Statin can reduce the incidence of epilepsy after cortical cerebral infarction. Atorvastatin is superior to rosuvastatin and simvastatin in reducing the incidence of epilepsy and the type of epilepsy, and does not increase the side effects of liver and kidney function damage and muscle enzyme elevation. It is a safe and effective drug for treating epilepsy after cortical cerebral infarction. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
